Prospective Study for Endometrial Carcinoma and Hyperplasia in Childbearing-age Women

The goal of this clinical trial is to evaluate the effect and adverse side effects of membrane-inhibiting formula plus oral progestins as fertility-preserving treatment in patients with early-stage endometrial cancer and endometrial hyperplasia research questions:When taken with oral progestins, does the drug membrane-inhibiting formula shorten the time required for complete endometrial remission? What medical problems do participants have when taking drug membrane-inhibiting formula plus oral progestins? Efficacy, side effects, recurrence, pregnancy, and time to obtain pregnancy in different

Trial Details

NCT ID
NCT06417736
Phase
NA
Sponsor
Women's Hospital School Of Medicine Zhejiang University
Status
RECRUITING
Cancer Type
Endometrial Cancer Uterine Cancer
Interventions
  • Megestrol Acetate 40 MG
Locations (sample)
  • Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

  • 18-45 years old with a strong desire to preserve fertility; 2. pathologically diagnosed with primary grade1 or grade2 endometrioid endometrial carc…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Endometrial Cancer Uterine Cancer Trials on Trialify →